AKT1 and acute myeloid leukemia: STAT3 shows an extensive and cell type-dependent variation in its preference to potential DNA binding sites [71, 72], and a similar variation between biologically heterogeneous AML patients may explain the different biological effects of PI3K-Akt-mTOR-STAT3 signaling between AML patients [73].